

*This report contains the collective views of an international group of experts and  
does not necessarily represent the decisions or the stated policy of the World Health Organization*

**WHO Technical Report Series**

**926**

---

# **WHO EXPERT COMMITTEE ON BIOLOGICAL STANDARDIZATION**

---

Fifty-third Report



---

**World Health Organization**  
**Geneva 2004**

WHO Library Cataloguing-in-Publication Data

WHO Expert Committee on Biological Standardization (2003 : Geneva, Switzerland)  
WHO Expert Committee on Biological Standardization : fifty-third report.

(WHO technical report series ; 926)

1.Biological products — standards 2.Vaccines — standards 3.Blood 4.Reference standards 5.Guidelines I.Title II.Series

ISBN 92 4 120926 7  
ISSN 0512-3054

(LC/NLM classification: QW 800)

**© World Health Organization 2004**

All rights reserved. Publications of the World Health Organization can be obtained from Marketing and Dissemination, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel: +41 22 791 2476; fax: +41 22 791 4857; email: [bookorders@who.int](mailto:bookorders@who.int)). Requests for permission to reproduce or translate WHO publications — whether for sale or for noncommercial distribution — should be addressed to Marketing and Dissemination, at the above address (fax: +41 22 791 4806; email: [permissions@who.int](mailto:permissions@who.int)).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

The World Health Organization does not warrant that the information contained in this publication is complete and correct and shall not be liable for any damages incurred as a result of its use.

This publication contains the collective views of an international group of experts and does not necessarily represent the decisions or the stated policy of the World Health Organization.

**Typeset in Hong Kong  
Printed in Singapore**

# Contents

<b>Introduction</b>	<b>1</b>
<b>General</b>	<b>1</b>
Developments in biological standardization	1
Scientific basis for preparation and characterization of International Standards	5
WHO biologicals web site	6
International Nonproprietary Names for biotechnology derived medicinal products	7
Feedback on WHO recommendations and guidelines and capacity building in quality assurance	8
<b>International recommendations, guidelines and other matters related to the manufacture and quality control of biologicals</b>	<b>8</b>
Recommendations for the production and quality control of smallpox vaccines	8
Guidelines for the safe production and quality control of poliomyelitis vaccine (inactivated)	9
Recommendations for the production and control of group C meningococcal conjugate vaccines (addendum)	10
Guidelines on regulatory expectations related to the elimination, reduction or replacement of thiomersal in vaccines	10
Requirements for the collection, processing and quality control of blood, blood components and plasma derivatives	11
Recommendations for the production and quality control of poliomyelitis vaccines (oral)	12
Stability evaluation of vaccines: regulatory expectations	12
Guidelines on nonclinical evaluation of vaccines: regulatory expectations	13
Gene transfer medicinal products	13
Task force on cell substrates	14
World Health Organization cell banks	14
Human and animal transmissible spongiform encephalopathies and the safety of biologicals	15
Requirements for diphtheria, tetanus, pertussis and combination vaccines	15
Proposals for discontinuation of Requirements and Guidelines	16
<b>International reference standards</b>	<b>17</b>
Recommendations for the preparation, characterization, and establishment of international and other biological reference standards	17
<b>Antibodies</b>	<b>17</b>
Anti-parvovirus B19 plasma	18
Anti-human platelet antigen 5b	18
<b>Antigens and related substances</b>	<b>18</b>
Flavivirus reference materials	18

<b>Blood products and related substances</b>	19
Anti-D immunoglobulin	19
Reference panel for human immunodeficiency virus-1 RNA genotype	19
Hepatitis A RNA	20
Hepatitis C RNA	21
Thrombin	21
Fibrinogen, plasma	22
<b>Cytokines, growth factors and endocrinological factors</b>	22
Erythropoietin	22
Interferon beta	23
<b>Diagnostic reagents</b>	23
Lipoprotein (a)	23
International Reference Materials for diagnosis and study of transmissible spongiform encephalopathies	23
WHO Consultation on International Standards for in vitro clinical diagnostic procedures based on nucleic acid amplification techniques	24
<b>Miscellaneous</b>	25
Mutant analysis by polymerase chain reaction and restriction enzyme cleavage assays for poliovirus	25
Papillomavirus reference materials	26
<b>Annex 1</b>	
Recommendations for the production and quality control of smallpox vaccine, revised 2003	27
<b>Annex 2</b>	
Guidelines for the safe production and quality control of inactivated poliomyelitis vaccine manufactured from wild polioviruses	65
<b>Annex 3</b>	
Recommendations for the production and control of group C meningococcal conjugate vaccines (Addendum 2003)	90
<b>Annex 4</b>	
Guidelines on regulatory expectations related to the elimination, reduction or replacement of thiomersal in vaccines	95
<b>Annex 5</b>	
Biological substances: international standards and reference reagents	103
<b>Annex 6</b>	
Recommendations and guidelines for biological substances used in medicine and other documents	105

# WHO Expert Committee on Biological Standardization

Geneva, 17–21 February 2003

## Members

- Dr W.G. van Aken, Amstelveen, the Netherlands (*Chairman*)
- Dr D. Calam, Pewsey, Wilts., England (*Rapporteur*)
- Dr M. Angeles Cortes Castillo, Directora de Control de Calidad, Instituto Nacional de Higiene, Mexico DF, Mexico
- Dr R. Dobbelaer, Head, Biological Standardization, Scientific Institute of Public Health — Louis Pasteur, Brussels, Belgium
- Dr F. Fuchs, Director — Lyon Site, Agence Française de Sécurité Sanitaire de Produits de Santé, Direction des Laboratoires et des Contrôles, Médicaments Immunologiques et Produits thérapeutiques, Lyon, France
- Dr A. Homma, Director, Bio-Manguinhos, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil (*Vice-Chairman*)
- Dr T. Kurata, Deputy Director-General, National Institute of Infectious Diseases, Tokyo, Japan
- Dr N.V. Medunitsin, Director, Tarasevic State Institute for the Standardization and Control of Medical Biological Preparations, Moscow, Russian Federation
- Dr F. Ofosu, Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, Canada

## Representatives of other organizations

*European Diagnostic Manufacturers Association*

Dr E. Völkert, Roche Diagnostics GmbH, Integrated Healthcare Diagnostics, Mannheim, Germany

*Council of Europe, European Department for the Quality of Medicines*

Mr J-M. Spieser, Head, Division IV, Biological Standardization and Official Medicines Control Laboratories Network, European Pharmacopoeia Commission, Strasbourg, France

*European Plasma Fractionation Association and Global Collaboration of Blood Safety*

Dr D. Armstrong, Natal Bioproducts Insitute, South Africa

*International Association of Biologicals*

Dr A. Eshkol, Vice President Scientific Affairs, Serono International SA, Geneva, Switzerland

*International Bureau of Weights and Measures*

Dr T. Quinn, Sèvres, France

*International Federation of Clinical Chemistry and Laboratory Medicine*

Professor J. Thijssen, Department of Endocrinology, University Hospital of Utrecht, Utrecht, the Netherlands

*International Federation of Pharmaceutical Manufacturers Associations*

Dr M. Duchêne, Director, Quality Control, GlaxoSmithKline Biologicals, Rixensart, Belgium

Dr A. Sabouraud, Director, Quality Control of Development Products, Aventis Pasteur SA, Marcy l'Etoile, France

*International Society on Thrombosis and Haemostasis*

Dr T. Barrowcliffe, National Institute for Biological Standards and Control, Potters Bar, Herts., England

*Plasma Protein Therapeutics Association*

Dr R. Büchel, Director, PPTA Source/European Plasma Collection Committee (PPTA), Brussels, Belgium

*United State Pharmacopeia*

Dr R. Dabbah, Director, Complex Actives Division, Information and Standard Development, Rockville, MD, USA

**Secretariat**

Dr A. Bristow, National Institute for Biological Standards and Control, Potters Bar, Herts., England (*Temporary Adviser*)

Dr T. Burnouf, Human Plasma Product Services, Lille, France (*Temporary Adviser*)

Dr K. Cichutek, Paul Ehrlich Institute, Langen, Germany (*Temporary Adviser*)

Dr M. Corbel, Division of Bacteriology, National Institute for Biological Standards and Control, Potters Bar, Herts., England (*Temporary Adviser*)

Dr R.H. Decker, Hepatitis and AIDS Research, Deerfield, Illinois, USA (*Temporary Adviser*)

Dr W. Egan, Deputy Director, Office of Vaccines, Center for Biologics Evaluation and Research, Food and Drug Administration, Rockville, MD, USA (*Temporary Adviser*)

Dr E. Griffiths, Associate Director-General, Biologics and Genetic Therapies Directorate, Health Canada, Ottawa, Ontario, Canada (*Temporary Adviser*)

Dr M.F. Gruber, Scientific Reviewer, Division of Vaccines and Related Products Application, Center for Biologics Evaluation and Research, Food and Drug Administration, Rockville, MD, USA (*Temporary Adviser*)

Dr Ian Gust, Department of Microbiology and Immunology, University of Melbourne, Parkville, Victoria, Australia (*Temporary Adviser*)

Dr S. Inglis, Director, National Institute for Biological Standards and Control, Potters Bar, Herts., England (*Temporary Adviser*)

Dr L. Jodar, Associate Director for Programmes, Institutional Development and Partnerships, International Vaccine Institute, Seoul, Republic of Korea (*Temporary Adviser*)

Dr J.G. Kreeftenberg, Bureau for International Cooperation, National Institute of Public Health and the Environment (RIVM), Bilthoven, the Netherlands (*Temporary Adviser*)

- Dr Lei Dianliang, Deputy Director, National Institute for the Control of Pharmaceutical and Biological Products, Beijing, People's Republic of China (*Temporary Adviser*)
- Dr N. Lelie, Viral Quality Control Unit, Sanquin-CLB, Alkmaar, the Netherlands (*Temporary Adviser*)
- Dr J. Löwer, Director, Paul Ehrlich Institute, Langen, Germany (*Temporary Adviser*)
- Dr P. Minor, Head, Division of Virology, National Institute for Biological Standards and Control, Potters Bar, Herts., England (*Temporary Adviser*)
- Dr G. Orefici, Department of Bacteriology, Istituto Superiore di Sanita, Rome, Italy (*Temporary Adviser*)
- Dr F. Reigel, Head, Swissmedic, Biological Medicines and Laboratories, Agency for Therapeutic Products, Berne, Switzerland (*Temporary Adviser*)
- Dr Y. Sohn, Director, Division of Biotechnology, Centre for Biologics Evaluation, Korean Food and Drug Administration, Seoul, Republic of Korea (*Temporary Adviser*)
- Dr M. Weinstein, Associate Deputy-Director, Office of Blood Research and Review, Center for Biologics Evaluation and Research, Food and Drug Administration, Rockville, MD, USA (*Temporary Adviser*)
- Dr D.J. Wood, Acting Coordinator, Quality Assurance and Safety of Biologicals, World Health Organization, Geneva, Switzerland (*Secretary*)

预览已结束，完整报告链接和二维码如下：

[https://www.yunbaogao.cn/report/index/report?reportId=5\\_30091](https://www.yunbaogao.cn/report/index/report?reportId=5_30091)

